Please login to the form below

Not currently logged in
Email:
Password:

monoclonal antibodies

This page shows the latest monoclonal antibodies news and features for those working in and with pharma, biotech and healthcare.

GSK agrees on 10% equity stake in mRNA specialist CureVac

GSK agrees on 10% equity stake in mRNA specialist CureVac

collaboration focused on the development of mRNA-based vaccines and monoclonal antibodies (mAbs).

Latest news

More from news
Approximately 2 fully matching, plus 83 partially matching documents found.

Latest Intelligence

  • Cortellis Drugs to Watch in 2020 report Cortellis Drugs to Watch in 2020 report

    Triptans are considered first-line therapy for the acute treatment of migraine and are widely available generically, although the market is undergoing transformation by prophylactic options such as CGRP monoclonal antibodies. ... It will face competition

  • Combined immunotherapies – potential and pitfalls Combined immunotherapies – potential and pitfalls

    The recent failed phase 3 trial of a combination of MSD’s monoclonal antibody Keytruda (pembrolizumab) and InCyte Corporation’s epacadostat in metastatic melanoma is a case in point he says. ... This has shaped industry development strategies, said

  • The good, the bad and the ugly The good, the bad and the ugly

    Three CGRP monoclonal antibodies will launch in the US for migraine in 2018 - with a fourth anticipated in 2019.

  • The tipping point The tipping point

    For example, since 2015, when the first monoclonal antibody biosimilar, infliximab, was launched in Europe we have seen a notable increase in the overall use of infliximab. ... For example, providing therapeutic drug monitoring (TDM) to minimise loss of

  • What makes the difference in the biosimilar battle? What makes the difference in the biosimilar battle?

    Taking the example of multiple blockbuster monoclonal antibodies close to their patent expiry dates, we can see that numerous big pharma companies like Merck, Amgen and Pfizer and even smaller to

More from intelligence
Approximately 0 fully matching, plus 17 partially matching documents found.

Latest appointments

  • F-star appoints GSK's Neil Brewis F-star appoints GSK's Neil Brewis

    Brewis joins from GlaxoSmithKline where he served as vice president and head head of biopharmaceutical research, leading a global team of 300 scientists who advanced numerous monoclonal antibodies, antibody fragments, and

  • V Bryan Lawlis joins board of KaloBios V Bryan Lawlis joins board of KaloBios

    patient-targeted, monoclonal antibodies towards commercialisation,” said David Pritchard, president and CEO of KaloBios. ... This includes three antibodies in development: one for inflammatory disease, one for lung infection and one for cancer.

More from appointments
Approximately 0 fully matching, plus 2 partially matching documents found.

Latest from PMHub

More from PMHub
Approximately 0 fully matching, plus 2 partially matching documents found.

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
Madmicrobe Studios

MadMicrobe is an award-winning team of animators and science experts creating photo real life-science animation content for the healthcare and...

Latest intelligence

InSite Mapping™ - a Novel Tool for Insight-gathering and Patient Journey Mapping
Learn how a client engaged 18 rheumatologist advisors over 6 months to create a patient journey map for SLE....
Alone we can do so little, together we can do so much
Collaboration is at the heart of successful patient engagement and effective healthcare provision. But in such a complex, nuanced network, true collaborations are rare. So how can we, as an...
7 important considerations for creating an inclusive clinical trial website
You might have noticed that all of us here at COUCH Health are big advocates for taking action to improve diversity and inclusion in the world of clinical research. ‘Taking...

Infographics